Western Blot: TRIF/TICAM1 Antibody [NB120-13810] - Analysis of TRIF in mouse spleen probed with TRIF antibody, in A: presence and B: absence of immunizing peptide, at 1:1000.
Immunocytochemistry/ Immunofluorescence: TRIF/TICAM1 Antibody [NB120-13810] - TRIF antibody was tested in A431 cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight ...read more
Western Blot: TRIF/TICAM1 Antibody [NB120-13810] - Analysis of TRIF in mouse A: Intestine. B: Spleen. C: RAW lysate using TRIF antibody at 1:1000 dilution.
Simple Western: TRIF/TICAM1 Antibody [NB120-13810] - Image shows a specific band for TRIF in 0.5 mg/mL of Raji lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.
In Simple Western only 10 - 15 uL of the recommended dilution is used per data point. Separated by Size-Wes, Sally Sue/Peggy Sue. The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. Use in Immunoprecipitation reported in scientific literature (PMID 28007523). Use in Immunoblotting reported in scientific literature (PMID 27043414)..
76 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Human reactivity reported in the scientific literature (PMID: 23777661). Rat reactivity reported in scientific literature (PMID: 23447644). Porcine reactivity reported in scientific literature (PMID: 27046485).
Packaging, Storage & Formulations
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
0.02% Sodium Azide
Alternate Names for TRIF/TICAM1 Antibody
Proline-rich, vinculin and TIR domain-containing protein B
PRVTIRBTIR domain-containing adapter protein inducing IFN-beta
TRIFToll-interleukin-1 receptor domain-containing adapter protein inducinginterferon beta
TICAM (Toll-interleukin 1 receptor domain (TIR)-containing adaptor molecule-1) or TRIF (Toll/IL-1 receptor domain-containing adapter inducing IFN-beta) plays an essential role in the MyD88-independent signaling of TLR3.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
FAQs for TRIF/TICAM1 Antibody (NB120-13810). (Showing 1 - 1 of 1 FAQs).
Regarding the WB testing for the TRIF/TICAM1 Antibody Cat# NB120-13810, can you confirm if the RAW lysate was treated in any way? Some of the antibody references on the product page indicate samples treated with LPS. Is there also any explanation for the molecular weight observed? The signal on mouse is right above the 66 kDa maker while the testing on Raji displays a band closer to 100 kDa.
The RAW lysate has not been treated in the western shown here. The difference in sizes can be explained as the mouse sample that is running right at 66 KD is a regular Western Blot, however, the band that is running at 100 KD is on the Simple Western system and tends to run larger than on a regular western blot. Protein Simple is the new line of proteins analysis technology:
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our TRIF/TICAM1 Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.